I do not know on what basis the Ars alb. and that potency and administration is adopted with any clinical approval.
Defineatly it will boost the faith of Ayush Padhti /system among the public. Lot of tnx.to Ayush Ministery.
Homoeopathy science is on symptoms with reportisation any drug can come ars album is polycrest medicine
Nice information Ayush 64 tablet? Available for practice?
Good article and information
Very informative post
Good post doctor
Cases that would interest you
- Login to View the image
Pregnant women do not appear more likely to contract the infection than the general population. However, pregnancy itself alters the body’s immune system and response to viral infections in general, which can occasionally be related to more severe symptoms and this will be the same for COVID-19. Transmission With regard to vertical transmission (transmission from mother to baby antenatally or intrapartum), emerging evidence now suggests that vertical transmission is probable, although the proportion of pregnancies affected and the significance to the neonate has yet to be determined. At present, there are no recorded cases of vaginal secretions being tested positive for COVID-19. At present, there are no recorded cases of breast milk being tested positive for COVID-19. Effect on Foetus There are currently no data suggesting an increased risk of miscarriage or early pregnancy loss in relation to COVID-19. There is no evidence currently that the virus is teratogenic. Long term data is awaited. COVID-19 infection is currently not an indication for Medical Termination of Pregnancy. General Guidelines for Obstetric Health Care Providers Ob-gyns and other health care practitioners should contact their local and/or state health department for guidance on testing persons under investigation and should follow the national protocol. Health care practitioners should immediately notify infection control personnel at their health care facility and their local or state health department in the event of a PUI for COVID-19. A registry for all women admitted to with confirmed COVID-19 infection in pregnancy should be maintained. Maternal and neonatal records including outcome should be completed in detail and preserved for analysis in future. Health care providers should create a plan to address the possibility of a decreased health care workforce, potential shortage of personal protective equipment, limited isolation rooms, and should maximize the use of telehealth across as many aspects of prenatal care as possible. Each facility should consider their appropriate space and staffing needs to prevent transmission of the virus that causes COVID-19. Pregnant women should be advised to increase their social distancing to reduce the risk of infection and practice hand hygiene. Health care practitioners should promptly notify infection control personnel at their facility of the anticipated arrival of a pregnant patient who has confirmed COVID-19 or is a PUI so that infection control measures can be kept in place. Intrapartum services should be provided in a way that is safe, with reference to minimum staffing requirements and the ability to provide emergency obstetric, anaesthetic and neonatal care where indicated. To read complete guidelines- https://icmr.nic.in/sites/default/files/upload_documents/Guidance_for_Management_of_Pregnant_Women_in_COVID19_Pandemic_12042020.pdfDr. Sambhavi Gupta14 Likes16 Answers
- Login to View the image
ONE PAGE COMPILATION OF COVID - 19 FACTS PDF download link: https://drive.google.com/file/d/1TcDy4hLy1FP3vMoK9coI-Cj5BXpIOAMU/view?usp=drivesdk (Source: WHO & Studies : Characteristics of and Important Lessons From the Coronavirus Disease 2019(COVID-19) Outbreak in China, Clinical Characteristics of Coronavirus Disease 2019 in China)Dr. Shashank Kumar Srivastav18 Likes10 Answers
- Login to View the image
Coronavirus Disease 2019 (COVID-19) Discharge Instructions Coronavirus disease 2019 is also known as COVID-19. It is a viral illness that infects the lungs. It is caused by a virus called SARS-associated coronavirus (SARS-CoV-2). This illness was first seen in late 2019 in China and has spread across the world. The signs of COVID-19 are like the flu, and you may have a cough, fever, and it may be hard to breathe. It spreads easily through droplets with the virus when you sneeze or cough. The germs also survive on surfaces like tables, door handles, and telephones. That means you can become sick if you touch a surface with the virus and then touch your face. What care is needed at home? • Ask your doctor what you need to do when you go home. Make sure you ask questions if you do not understand what the doctor says. • Drink lots of water, juice, or broth to replace fluids lost from a fever. • You may use cool mist humidifiers to help ease congestion and coughing. • Use 2 to 3 pillows to prop yourself up when you lie down to make it easier to breathe and sleep Do not smoke and do not drink beer, wine, and mixed drinks (alcohol). • To lower the chance of passing the infection to others: o Wash your hands often. o Do not make food for others. o Stay home in a separate room, except to get medical care. o Wear a mask if you are around others who are not sick. o Use a separate bathroom if possible. What drugs may be needed? The doctor may order drugs to: • Help with breathing • Help with fever • Help with swelling in your airways and lungs • Control coughing • Ease a sore throat • Help a runny or stuffy nose To read more-http://healthclarity.wolterskluwer.com/content/dam/wk-healthclarity/documents/COVID/wk-emmi-covid-19-discharge-instructions.pdf Source- Wolters Kluwer, CDC, WHODr. Pushker Mehra8 Likes8 Answers
- Login to View the image
Therapeutic Potential for Tetracyclines in the Treatment of COVID‐19 This article is protected by copyright. All rights reserved Conflict of interest: The authors declare no conflicts of interest. Currently there is a race against time to identify prophylactic and therapeutic treatments against COVID-19. Until these treatments are developed, tested and mass produced, it might be prudent to look into existing therapies that could be effective against this virus. Based on the available evidence we believe that tetracyclines may be effective agents in the treatment of COVID-19. Tetracyclines (e.g. tetracycline, doxycycline, and minocycline) are highly lipophilic antibiotics that are known to chelate zinc compounds on matrix metalloproteinases (MMPs). Coronaviruses are also known to heavily rely on host MMPs for survival, cell infiltration, cell to cell adhesion, and replication, many of which have zinc as part of their MMP complex. It is possible that the zinc chelating properties of tetracyclines may also aid in inhibiting COVID-19 infection in humans limiting their ability to replicate within the host. Tetracyclines might be also able to inhibit RNA replication on positive-sense single stranded RNA, like COVID-19. For example, one study deduced a mechanism discerning how doxycycline could potentially treat the dengue virus. They also showed that at normal human body temperature and fever conditions, doxycycline significantly inhibited the virus’ own serine protease as well as noting a concentration dependent decrease in viral replication. They also found that doxycycline inhibited the post infection replication in addition to reducing the viruses’ ability to enter the cultured cells. Another study showed that retroviral load was decreased by 70% when cells were treated with the doxycycline at human body temperature We believe that tetracyclines can be potential therapeutic agents for COVID-19 that is hiding in plain sight. Moreover, tetracyclines overall are much safer agents than other potential agents that have been considered to treat COVID-19, such as chloroquine or antiretroviral drugs. We strongly urge international research groups to consider investigating the potential therapeutic efficacy of tetracycline antibiotics in treating COVID-19. To read more- https://accpjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/phar.2395 Source- accpjournalsDr. Rama Chauhan9 Likes7 Answers
- Login to View the image
Annals of Oncology: Managing COVID-19 in the oncology clinic and avoiding the distraction effect The safety and management of cancer patients in the current SARS-CoV-2 outbreak is urgent and most cancer clinics need to establish a contingency plan. It is well established that cancer patients are more susceptible to infections because of the immuno-suppressive state caused by both anticancer treatments and surgery. A recent study from Prof He and colleagues shows that the risk of developing severe events in COVID-19 disease is statistically significant higher in patients with cancer, with a hazard ratio of 3.56. A caution in interpreting the data is that the patient numbers are of course small, but the results are not unexpected. The authors suggest that postponing adjuvant chemotherapy or elective surgery for less aggressive cancers should be considered and that the increased risk for personal protection provisions should be emphasized for patients with cancer or cancer survivors. Furthermore, more intensive surveillance or treatment should be considered for those patients with cancer who are infected with SARS-CoV-2 virus. It is well established that delayed oncologic surgery may lead to disease progressions and result in tumors no longer resectable, leading to worse survival outcomes. The same goes for neoadjuvant or adjuvant chemotherapy regimens administered with suboptimal timing. It should be emphasized that we are talking about patients potentially cured by oncologic treatments. Therefore, any delay of these fundamental procedures, either intentional or due to shortage of personnel, should be avoided. The same risk is present for the people who have scheduled screening activities (e.g. screening mammography for the early diagnosis of breast cancer). To Read complete article- https://www.annalsofoncology.org/article/S0923-7534(20)36373-0/pdf Reference- Annals of Oncology Authors- Cortiula Francesco, Aleksandra Pettke, Bartoletti Michele, Puglisi Fabio, Thomas HelledayDr. Pushker Mehra12 Likes4 Answers